BRUSSELS/LONDON, Nov 22 (Reuters) - EU antitrust

regulators are set to clear without conditions Novo Holdings'

planned $16.5 billion takeover of Catalent ( CTLT ), a person

with direct knowledge of the matter said on Friday.

Novo Holdings is the controlling shareholder of Danish

drugmaker Novo Nordisk, whose profits from

blockbuster weight-loss drug Wegovy has made it Europe's most

valuable company by market value.